The Food and Drug Administration (FDA) has approved the use and marketing of Contrave, a new weight loss pill for the US market. This is the third weight loss pill to be approved by the FDA within two years, and Contrive has been noted to be marketed by Takeda Pharmaceutical, Japan. The other two weight loss medications that were earlier approved for US users by the FDA are Qsymia and Belviq.
Contrave has two active drug components, and it is a combination of naltrexone and bupropion. Naltrexone has been found effective for treating alcohol and drug dependence, and bupropion has been found effective as an antidepressant drug for treating mood disorders, and it is also recommended for smoking withdrawal treatments. However, Contrave has been approved for treating overweight and obese persons, and for treating medical conditions like diabetes that are related to weight gain.
According to Jean-Marc Guettier, an FDA official, “obesity continues to be a major public health concern. When used as directed in combination with a healthy lifestyle that includes a reduced calorie diet and exercise, Contrave provides another treatment option.”
But the FDA has warned that possible side effects of using the new drug are suicidal thoughts and increase in blood pressure and heart rate. It also warns manufacturers of obesity drugs to conduct proper long term tests into safety and side effect issues related to the use of the drugs, and then submit proper reports to the agency within an approved time-frame.